Boehringer Ingelheim GmbH Ends Female Desire Drug Flibanserin Development After FDA's Safety Query

Published: Oct 08, 2010

Oct. 8 (Bloomberg) - Boehringer Ingelheim GmbH abandoned development of its female desire drug flibanserin after U.S. regulators said the pill wasn’t proven to be safe and effective.

Back to news